Filing Details

Accession Number:
0001567619-22-020800
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-11-23 09:38:16
Reporting Period:
2022-11-21
Accepted Time:
2022-11-23 09:38:16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1692830 Satsuma Pharmaceuticals Inc. STSA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1373603 Michael Braden Leonard 65 E Cedar - Suite 2
Zionsville IN 46077
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-11-21 150,000 $0.71 150,000 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 6,440,000 Indirect Holding of BML Investment Partners, L.P.
Footnotes
  1. BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein
  2. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.70 to $0.73. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.